Sugi Predict

Sugi Predict / Compounds / SCHEMBL17293485

SCHEMBL17293485

SCHEMBL17293485

CC(C)(C)c1nc2ccc(Cl)c(S(=O)(=O)N3CCCC3)c2o1

nearest known ligand 0.41

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 6/20 0.40
▸ TSHR P16473 3/20 0.39
▸ L3MBTL1 Q9Y468 3/20 0.39
▸ KDM4E B2RXH2 2/20 0.39
▸ LMNA P02545 2/20 0.39
▸ POLB P06746 1/20 0.39
▸ GAA P10253 1/20 0.39
▸ ALOX15 P16050 1/20 0.39
▸ MAPT P10636 2/20 0.38
▸ NPSR1 Q6W5P4 1/20 0.38
▸ MEN1 O00255 1/20 0.38
▸ KMT2A Q03164 1/20 0.38
▸ ATM Q13315 1/20 0.38
▸ MAPK1 P28482 2/20 0.37
▸ HTT P42858 1/20 0.36
▸ SMN1; SMN2 Q16637 1/20 0.36
▸ ELANE P08246 1/20 0.36
▸ TDP1 Q9NUW8 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17293323 0.99 TSHR (0.41) ALDH1A1TSHRL3MBTL1KDM4ELMNA
SCHEMBL5711780 0.91 RAB9A (0.46) ALDH1A1L3MBTL1LMNAPOLBMEN1
SCHEMBL17293536 0.90 ALDH1A1 (0.44) ALDH1A1TSHRL3MBTL1KDM4ELMNA
SCHEMBL1563090 0.90 POLB (0.45) ALDH1A1L3MBTL1LMNAPOLBMAPT
SCHEMBL2772819 0.90 CYP3A4 (0.46) ALDH1A1TSHRLMNAMAPTNPSR1
SCHEMBL13774876 0.89 USP2 (0.43) ALDH1A1TSHRKDM4ELMNAMAPT
SCHEMBL9978081 0.89 SPR (0.35) ALDH1A1TSHRKDM4ELMNAMAPT
SCHEMBL5711785 0.88 ALDH1A1 (0.46) ALDH1A1KDM4EGAAMEN1KMT2A
SCHEMBL17293478 0.87 MAPT (0.33) ALDH1A1KDM4ELMNAPOLBMAPT
SCHEMBL17293383 0.87 HSD11B1 (0.42) ALDH1A1KDM4ELMNAGAAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-107027306-B 1- (cyclopent-2-en-1-yl) -3- (2-hydroxy-3- (arylsulfonyl) phenyl) urea derivatives as CXCR2 inhibitors 葛兰素史密斯克莱知识产权发展有限公司 2020-05-05 — — CN disclosed
US-10336719-B2 1-(cyclopent-2-en-1-yl)-3-(2-hydroxy-3-(arylsulfonyl)phenyl)urea derivatives as CXCR2 inhibitors GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2019-07-02 — — US disclosed
US-10336719-B2 1-(cyclopent-2-en-1-yl)-3-(2-hydroxy-3-(arylsulfonyl)phenyl)urea derivatives as CXCR2 inhibitors GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2019-07-02 — — US disclosed
US-20190010135-A1 Novel Compounds GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2019-01-10 — — US disclosed
US-10106515-B2 1-(cyclopent-2-en-1-yl)-3-(2-hydroxy-3-(arylsulfonyl)phenyl)urea derivatives as CXCR2 inhibitors GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2018-10-23 — — US disclosed
EP-3148963-B1 1-(CYCLOPENT-2-EN-1-YL)-3-(2-HYDROXY-3-(ARYLSULFONYL)PHENYL)UREA DERIVATIVES AS CXCR2 INHIBITORS GLAXOSMITHKLINE IP DEV LTD (GB) 2018-06-13 — — EP disclosed
EP-3148963-B1 1-(CYCLOPENT-2-EN-1-YL)-3-(2-HYDROXY-3-(ARYLSULFONYL)PHENYL)UREA DERIVATIVES AS CXCR2 INHIBITORS GLAXOSMITHKLINE IP DEV LTD (GB) 2018-06-13 — — EP disclosed
US-20170190681-A1 1-(CYCLOPENT-2-EN-1-YL)-3-(2-HYDROXY-3-(ARYLSULFONYL)PHENYL)UREA DERIVATIVES AS CXCR2 INHIBITORS Glaxosmithline Intellectual Property Development Limited (GB) 2017-07-06 — — US disclosed
US-20170190681-A1 1-(CYCLOPENT-2-EN-1-YL)-3-(2-HYDROXY-3-(ARYLSULFONYL)PHENYL)UREA DERIVATIVES AS CXCR2 INHIBITORS Glaxosmithline Intellectual Property Development Limited (GB) 2017-07-06 — — US disclosed
US-20170190681-A1 1-(CYCLOPENT-2-EN-1-YL)-3-(2-HYDROXY-3-(ARYLSULFONYL)PHENYL)UREA DERIVATIVES AS CXCR2 INHIBITORS Glaxosmithline Intellectual Property Development Limited (GB) 2017-07-06 — — US disclosed
EP-3148963-A1 1 -(CYCLOPENT-2-EN-1 -YL)-3-(2-HYDROXY-3-(ARYLSULFONYL)PHENYL)UREA DERIVATIVES AS CXCR2 INHIBITORS GlaxoSmithKline Intellectual Property Development Limited (GB) 2017-04-05 — — EP disclosed
WO-2015181186-A1 1 -(CYCLOPENT-2-EN-1 -YL)-3-(2-HYDROXY-3-(ARYLSULFONYL)PHENYL)UREA DERIVATIVES AS CXCR2 INHIBITORS GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2015-12-03 — — WO disclosed
WO-2015181186-A1 1 -(CYCLOPENT-2-EN-1 -YL)-3-(2-HYDROXY-3-(ARYLSULFONYL)PHENYL)UREA DERIVATIVES AS CXCR2 INHIBITORS GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2015-12-03 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10106515-B2 1-(cyclopent-2-en-1-yl)-3-(2-hydroxy-3-(arylsulfonyl)phenyl)urea derivatives as CXCR2 inhibitors CXCR2, CXCR1, CXCR3 ALDH1A1 1467/4885TSHR 2300/4885L3MBTL1 4255/4885
US-20170190681-A1 1-(CYCLOPENT-2-EN-1-YL)-3-(2-HYDROXY-3-(ARYLSULFONYL)PHENYL)UREA DERIVATIVES AS CXCR2 INHIBITORS CXCR2, CXCR1, CXCR3 ALDH1A1 1572/4885TSHR 2142/4885L3MBTL1 4262/4885
US-10336719-B2 1-(cyclopent-2-en-1-yl)-3-(2-hydroxy-3-(arylsulfonyl)phenyl)urea derivatives as CXCR2 inhibitors CXCR2, CXCR1, CXCR3 ALDH1A1 1449/4885TSHR 2448/4885L3MBTL1 4230/4885
US-20190010135-A1 Novel Compounds CXCR2, CXCR1, CXCR3 ALDH1A1 1918/4885TSHR 2718/4885L3MBTL1 4595/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback